

**Industria y Comercio**

SUPERINTENDENCIA

02 080222 00

**PETITORIO**

SUPERINDUSTRIA Y COMERCIO

Radicación : 02090222 00000000

Folios: 54
ación

Fecha (MM/DD): 2002-10-07 16:36:27

Trámite : 011 PCT-PATENT 379 FASE NACI 411 PRESENTM

Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

FORMULARIO UNICO DE SOLICITUD DE PATENTE PCT ENTRADA EN FASE NACIONAL

1

SOLICITUD DE:

☒ Patente de Invención.☐ Patente de Modelo de Utilidad.☐ Capítulo I.☒ Capítulo II.

2

SOLICITANTE
(71)Nombre: PENFORD AUSTRALIA LIMITED
sociedad constituida y existente bajo las
leyes de Australia.Dirección: 170 Epping Road, Lane, Cove
NSW 2066, AustraliaDomicilio: Lane Cove,
Australia.

IDENTIFICACION

C.C.

☐

NIT

☐

C.E.

☐

Otro

☐

Cual

Número:

3

REPRESENTANTE
O APODERADO

Nombre: EMILIO FERRERO

Dirección: Carrera 4ª. No. 72-35

Teléfono: 347 36 11

Fax:: 217 92 11

E-mail: clientes@camyo.com.

Domicilio: Bogotá, Colombia.

IDENTIFICACION

C.C.

☒

NIT

☐

C.E.

☐

Otro

☐

Cual

Número: 438.019 T.P. 31.929

4

INVENTOR (ES)
(72)1- Ian Lewis BROWN
18 Valley Way,
Gymea, NSW 2227
Australia.3- Marc Andrew BROWN
8970 SW Sagert,
Tualatin, Oregon 97062
Estados Unidos de América.5- Linda Clare TAPSELL
40 Stanwell Avenue,
Stanwell Park, NSW 2058
Australia.2- Leonard Henry STORLIEN .
Snohøjdsgtten 16,
S-431 39 Molndal,
Suecia.4- Janine HIGGINS
4295 E. Mexico Avenue,
Denver, Colorado 80262,
Estados Unidos de América.

5

PCT (86)

Solicitud Internacional No. PCT/AU 01/00392Fecha: 6 de abril de 2001Publicación Internacional No. WO 01/76394 A1Fecha : 18 de octubre 2001

6

Título (54) METABOLISMO DE SUBTIPOS DE ALMIDONES Y LIPIDOS

7

Clasificación Internacional (51) A 23 L 1/308 , 1/30

8

Prioridad

SI ☒ NO ☐

(33) País de Origen

AU.

(32) Fecha

6 de abril de 2000

(31) Número de Solicitud

PQ 6733

9

Comprobante de pago No.: _____ Fecha: _____


10

Anexos:

- ☒ Comprobante de pago de la tasa de presentación de la solicitud por 378.000.00.
- ☐ Comprobante de pago por reivindicación de prioridad.
- ☐ Documento que acredita la existencia y representación legal cuando el solicitante sea persona jurídica.
- ☐ Poderes, si fuere el caso.
- ☐ Documento de cesión del inventor al solicitante o a su causante.
- ☐ Declaraciones.
- ☒ Copia de la solicitud internacional. (Resumen, descripción, reivindicaciones, dibujos)
- ☐ Traducción de la solicitud Internacional al castellano. (Resumen, descripción, reivindicaciones, dibujos)
- ☐ Copia del examen preliminar efectuado por la IPEA.
- ☐ Traducción del examen preliminar efectuado por la IPEA.
- ☐ De ser el caso, copia del contrato de acceso.
- ☐ De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas.
- ☐ De ser el caso, certificado de depósito del material biológico.
- ☐ Arte final 12x12
- ☐ De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extranjero por el mismo titular o su causante, relacionadas parcial o totalmente con la invención de esta solicitud.
- ☐ Otros

11

FIGURA CARACTERISTICA:



12

Solicito la concesión de la patente,

NOMBRE: EMILIO FERRERO

FIRMA : 
C.C. 438.019 de Usaquén T.P. 31.929

CCP

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/76394 A1

- (51) International Patent Classification⁷: A23L 1/308, 1/30 [AU/AU]; 40 Stanwell Avenue, Stanwell Park, NSW 2058 (AU).
- (21) International Application Number: PCT/AU01/00392 /
- (22) International Filing Date: 6 April 2001 (06.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: PQ 6733 6 April 2000 (06.04.2000) AU
- (71) Applicant (for all designated States except US): PENFORD AUSTRALIA LIMITED [AU/AU]; 170 Epping Road, Lane Cove, NSW 2066 (AU).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BROWN, Ian, Lewis [AU/AU]; 18 Valley Way, Gymea, NSW 2227 (AU). STORLIEN, Leonard, Henry [AU/SE]; Snobofdsilgen 16, S-431 39 Molndal (SE). BROWN, Marc, Andrew [US/US]; 8970 SW Sagert, Tualatin, OR 97062 (US). HIGGINS, Janice, [AU/US]; 4295 E. Mexico Avenue, Denver, CO 80262 (US). TAPSELL, Linda, Clare
- (74) Agent: F B RICE & CO; 605 Darling Street, Balmain NSW 2041 (AU).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, **CR**, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/76394 A1

(54) Title: STARCH SUB-TYPES AND LIPID METABOLISM

(57) Abstract: A method is provided for regulating carbohydrate and fat metabolism in an individual which method comprises replacing a proportion of the individual's daily carbohydrate intake with resistant starch and a proportion of the individual's saturated fat intake with unsaturated fat. Also provided are compositions comprising resistant starch and unsaturated fats and methods for making and using the same.

STARCH SUB-TYPES AND LIPID METABOLISM

Field of the invention

The present invention relates to the regulation of fat or lipid metabolism by means of compositions and diets which are high in resistant
5 starch and unsaturated fats.

Background to the invention

Obesity and overweight in general as well as a range of metabolic diseases such as non-insulin dependent diabetes mellitus, dislipidemias,
10 hypertension and coronary heart disease are a widespread problem in large parts of the world. In many cases, the underlying cause of these diseases is the development of insulin resistance. The factors which contribute to the onset and development of insulin resistance have not been fully elucidated but the type of fat and/or carbohydrate in the diet have been exposed as crucial factors
15 (Storlien et al., 1993, Diabetes, 42: 457-462).

Dietary starch, an important component of human carbohydrate intake, is composed of two types of glucose polymer, namely amylose and amylopectin. Amylose is a linear polymer of glucose residues linked by α 1-4) bonds whereas amylopectin is a branched polymer of glucose residues linked
20 by α (1-4) and α (1-6) bonds.

Ingestion of amylopectin starch is known to produce a rapid and prolonged rise in plasma insulin and glucose concentrations which has been postulated to be detrimental to whole body insulin sensitivity in the long term. In humans, consumption of foods which cause a large rise in postprandial
25 plasma glucose concentration is also associated with an increased concentration of free fatty acids in the plasma. This increase in plasma free fatty acid concentration causes a decrease in glucose oxidation, presumably via the glucose-fatty acid cycle, which may impair insulin sensitivity.

Summary of the invention

The present inventors have now shown that consumption of a diet high in resistant starch and unsaturated fats or lipids results in desirable effects on carbohydrate and fat metabolism. Specifically, it has been shown that consumption of a diet high in resistant starch and unsaturated fats or lipids leads to reduced post-prandial plasma glucose concentrations after meal intake, as well as lower plasma insulin levels; a reduction in plasma leptin concentrations together with an increase in satiety; and a decrease in the levels of lipid deposition in white adipose tissue, brown adipose tissue and muscle tissue together with an increase in glycogen synthesis in the liver.

Accordingly, the present invention provides in a first aspect, a method for regulating carbohydrate and fat metabolism in an individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.

Specific embodiments include:

(1) a method for enhancing fat metabolism in an individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.

Preferably, the enhancement of fat metabolism includes a reduction in fat accumulation and/or an increase in fat oxidation.

(2) a method for reducing plasma leptin concentrations and increasing satiety in an individual, which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.

(3) a method of treating an individual suffering from obesity, which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.

(4) a method of lowering the risk of obesity in an individual, which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.

5 (5) a method of lowering the risk of non-insulin dependent diabetes mellitus in an individual, which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.

(6) a method of reducing the post-prandial plasma glucose and/or
10 insulin levels in an individual following food consumption by the individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.

(7) a method of controlling an individual's body fat composition which
15 method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.

In a second aspect, the present invention provides a method of preparing a foodstuff for use in a method according to the first aspect which
20 method comprises substituting constituents with a low resistant starch content with constituents with a high resistant starch content and substituting some or all of the saturated fats with unsaturated fats.

In a third aspect the present invention provides a composition comprising at least 2g of resistant starch and at least 2g of unsaturated fat
25 wherein the resistant starch is present in a proportion of at least 5% by weight of the total starch content.

Preferably, the unsaturated fat is present in a proportion of at least 25% by weight of the total fat content.

Preferably the unsaturated fat is selected predominantly from poly-
30 unsaturated fats, with a good balance between omega-3 and omega-6 types, and mono-unsaturated fats.

The composition may, for example, be in the form of a tablet, a foodstuff, a component of a prepackaged meal or a component of a calorie-controlled diet.

In a fourth aspect, the present invention provides a method for
5 regulating carbohydrate and fat metabolism in an individual which method comprises administering to the individual a composition of the invention.

Specific embodiments include:

(1) a method for reducing plasma leptin concentrations and increasing satiety in an individual, which method comprises administering to the
10 individual a composition of the invention.

(2) a method of treating an individual suffering from obesity, which method comprises administering to the individual a composition of the invention.

(3) a method of lowering the risk of obesity in an individual, which
15 method comprises administering to the individual a composition of the invention.

(4) a method of lowering the risk of non-insulin dependent diabetes mellitus in an individual, which method comprises administering to the individual a composition of the invention.

(5) a method of reducing the post-prandial plasma glucose and/or
20 insulin levels in an individual following food consumption by the individual which method comprises administering to the individual a composition of the invention.

(6) a method of controlling an individual's body fat composition
25 which method comprises administering to the individual a composition of the invention.

The present invention also provides a composition of the invention for use in a method according to the fourth aspect of the invention. The present invention further provides the use of a composition of the invention in the
30 manufacture of a medicament for use in a method according to the fourth aspect of the invention.

The present invention also provides a method of enhancing fat utilisation in a diet of an individual, the method comprising consuming in a given meal at least 2 g of resistant starch with the fat to be utilised.

The present invention further provides a method of lowering the incidence of obesity in an individual through the stimulation of increased levels of fat oxidation, the method comprising placing the individual on a high carbohydrate diet, rich in resistant starch to stimulate increased levels of fat oxidation in the individual.

A method is also provided for lowering the incidence of non-insulin dependent diabetes mellitus in an individual, the method comprising placing the individual on a high carbohydrate diet, rich in resistant starch, to stimulate increased levels of fat oxidation in the individual.

Detailed description of the invention

15

Compositions and foodstuffs

The present invention provides compositions comprising high levels of resistant starch and unsaturated fat.

As used in this specification, the term "resistant starch" includes those forms defined as RS1, RS2, RS3 and RS4 as defined in Brown, McNaught and Moloney (1995) Food Australia 47: 272-275. Either modified or unmodified resistant starches or mixtures thereof can be used in the present invention. A particular resistant starch can be the product of multiple modifications. Modified resistant starches include breakdown products such as resistant maltodextrins.

One form of resistant starch particularly suitable for the present invention is starch containing resistant starch. Preferably, the starches have an amylose content of at least 40% (w/w), although the amylose content of the starch may vary depending on the plant species from which the starch has been obtained. In a preferred form the starch is from maize having an amylose content of at least 70% (w/w), at least 80% (w/w) or at least 90% (w/w). The

starch can also be chemically, physically, or enzymically treated or modified. Chemical modification can be by oxidation, cross-bonding, etherification, esterification, acidification, dextrinisation, or mixtures thereof. Physical modification includes heat-moisture treatment.

5 Preferably the resistant starches are derived or obtained from maize (corn). It will be appreciated, however, that other sources of resistant starch could be used in the present invention. Examples include cereals like sorghum, wheat, barley, oats, triticale, maize and rice, tubers like potatoes and tapioca, legumes such as peas, and others including starches derived from
10 conventional inbred breeding techniques or from genetically modified plant species.

 Starches can also be treated to enhance the resistant starch content by a number of physical or chemical means. Where the starch has been obtained from non-genetically modified plant species, the resulting treated starch can
15 still be termed non-GMO resistant starch. For a number of reasons relating to the regulation of GMO foods and consumer preference, it may be desirable to use only non-GMO starch, whether treated or untreated, in compositions of the invention.

 One preferred treatment means is to heat-treat starch in the presence of
20 moisture (heat-moisture treatment) which can be achieved by a number of processes including heating under negative, atmospheric or positive pressure under elevated moisture, or cycling techniques through different temperatures and pressures. Heating can be in the order of 100 to 180°C, preferably around 120 to 150°C and moisture levels of 10 to 80%, preferably 20 to 60%. Repeated
25 autoclaving and rapid cooling can also be used to increase the resistant starch content of starches. It will be appreciated that these processes and conditions can be changed to achieve the desired increase in the level of resistant starch in the starch being treated.

 Treatment can also be by solvent extraction to remove fats and/or
30 minerals from the starch.

In WO 94/03049 and WO 94/14342, high amylose starches are disclosed which are resistant starches and include maize starch having an amylose content of 50% (w/w) or more, particularly 80% (w/w) or more, rice starch having an amylose content of 27% (w/w) or more, or a wheat starch having 35% (w/w) or more. Furthermore, particular granular size ranges of starches having an amylose content of 50% or more and enhanced resistant starch content, these starches including maize, barley, and legumes. This invention is not, however, limited to these forms of resistant starch. For example, other forms of resistant starch can be derived from sources such as bananas and tubers such as potatoes and modified forms thereof.

Chemical modifications, such as oxidation, cross-bonding, etherification, esterification, acidification, dextrinisation and the like are well known in this art as being suitable chemical treatments. Similarly, other modifications can be induced physically, enzymically or by other means well known to those skilled in the art.

It may also be useful to modify the degree of enzyme susceptibility of the resistant starch by altering the conformation or structure of the starch. Examples include acid or enzyme thinning and cross bonding using difunctional reagents, heat/moisture treatment and thermal annealing. Modification of the starch may also be carried out by manipulation of the crystalline nature of the starch. Such modification methods are known to the art and starches produced by these methods would be suitable for the present invention.

Preferably, the resistant starch is derived from maize, sorghum, rice, barley, oats, triticale, wheat, legumes, potato, or banana starches. As the amylose content of some starches appears to be related to the resistant starch content, one preferred embodiment is the use of starches having an amylose content of at least 40% (w/w). Resistant starch obtained or derived from maize starch has been found to be particularly suitable for the present invention. In many starch-containing plants, the amylose content does not need to increase to the high levels found in maize in order for them to demonstrate the

properties of resistant starch. These properties are likely to be found in wheat [+35% amylose], banana and barley [+30% amylose]; potato, legumes and rice [+27% amylose]. The amount of resistant starch can be demonstrated by the resistance of the starch granule or starch derived material to attack by amylases, irrespective of its amylose content. However, the amylose content can act as an indicator of whether the starch granule will exhibit this property of resistance to amylolysis.

Maize starches having an amylose content of at least 70% (w/w), at least 80% (w/w) or at least 90% (w/w) are preferred as these starches contain high levels of starch granules forming resistant starch.

The term "unsaturated fats" includes unsaturated fatty acid esters in both solid and liquid form. The terms fats, oils, fatty acids and lipids are used interchangeably herein.

Preferably, the fat is a mono-unsaturated fat, a poly-unsaturated fat, an omega-3 fat, or an omega 6 fat. Further vegetable triglycerides relevant to the present invention include those obtained from seeds, beans, fruits, nuts and other plant materials, often obtained by mechanical expelling and/or solvent extraction. Examples which are particularly suitable for use in the present invention are sunflower oil including high and mid oleic varieties, soybean oil, cottonseed oil, canola or rapeseed oil including low linolenic and other modified varieties, flax or linseed oil including high linolenic varieties [Linola], maize or corn oil, olive oil, peanut oil, rice bran oil, palm oil and fractionated palm oils, palm kernel oil, coconut oil and the like.

Triglycerides of animal origin can be used in the present invention and include those obtained from milk and from the processing of cattle, sheep and fish. Preferred examples include n-3 polyunsaturated fatty acids (PUFAs) and n-6 PUFAs, such as fish oils.

Compositions according to the present invention comprise high levels of resistant starch and high levels of unsaturated fat as a proportion of carbohydrate/fat content compared with typical foodstuffs and dietary

supplement. Specifically, compositions of the present invention comprise at least 2g of resistant starch and 2g of unsaturated fat.

Thus compositions may comprise at least 5, 10, 15 or 20g of resistant starch. Since one of the aims of the present invention is to replace dietary starch of the non-resistant type, such as amylopectin starch, with resistant starch, it is preferred that the resistant starch is present as a significant proportion of the total starch content of the composition. For example the resistant starch may be present in a proportion of at least 10% by weight of the total starch content, preferably at least 15, 20, 25, 30, 35, 40, 50, 60, 70 or 80% by weight of the total starch content. Similarly, it is preferred that resistant starch is present as a significant proportion of the total carbohydrate content of the composition. For example the resistant starch may be present in a proportion of at least 5% by weight of the total carbohydrate content, preferably at least 10, 15, 20, 25, 30, 35, 40, 50, 60 or 75% by weight of the total carbohydrate content. Types of resistant starch that may be included in the compositions are described above.

In relation to the fat/lipid content, compositions typically comprise at least 2g of unsaturated fat or its equivalent. For example compositions may comprise at least 3, 4, 5, 6 or 8g of unsaturated fat [higher for food spreads such as margarine]. It is preferred to include unsaturated fat such that the ratio of resistant starch to unsaturated fat is from about 1:1 to 1:2, although the ratio can be markedly different for an individual food which is used in the context of the diet of an individual.

Since one of the aims of the present invention is to replace saturated fats with unsaturated fats to achieve the desired metabolic effects that have now been shown to occur when both resistant starch and unsaturated fats form a significant element of an individual's diet, it is preferred that the unsaturated fat is present as a significant proportion of the total fat content of the composition. For example the unsaturated fat may be present in a proportion of at least 25% by weight of the total fat content, preferably at least 35, 50, 75 or 80% by weight of the total starch content. In one embodiment, saturated fat

is substantially absent from the composition. Types of unsaturated fat that may be included in the compositions are described above.

Compositions may further comprise carbohydrate sources other than resistant starch, saturated fats, flavouring agents, vitamins, minerals, electrolytes, trace elements and other conventional additives. Proteins, particularly proteins resistant to digestion and termed "by-pass proteins or resistant proteins", may also be included to ensure optimal physiological performance or utilisation. If any of these optional ingredients are not present in the composition of the invention, they should normally be supplied as a supplement to the composition of the invention in other elements of the diet, so that an adequate supply of all essential nutritional ingredients is ensured. If the composition of the invention is intended to supply a substantial part of the food intake of a subject, the optional ingredients are preferably present, so that separate intake thereof can be avoided. This is of particular importance for overweight or obese subjects on a weight reduction treatment, by which it is important that all essential nutritional ingredients are supplied in recommended amounts.

Vitamins and minerals may be added to the composition in accordance with the limits laid down by health authorities. The composition of the invention may comprise all recommended vitamins and minerals. The vitamins will typically include A, B1, B2, B12, folic acid, niacin, panthotenic acid, biotin, C, D, E and K. The minerals will typically include iron, zinc, iodine, cobber, manganese, chromium and selenium. Electrolytes, such as sodium, potassium and chlorides, trace elements and other conventional additives are also added in recommended amounts.

The composition of the invention may take any form which is suitable for human or animal consumption, such as a foodstuff or drink. In one embodiment, the composition is a powdery mixture which is soluble, suspendable, dispersible or emulsifiable in a water-containing liquid such as water, coffee, tea or fruit juice. For such purpose, the composition may be packed in a package intended for covering the total nutrition requirement for a

defined period of time, such as three days or a week, whereby the composition will be divided into suitable sub-units of a daily dose, preferably four to five sub-units for women and four to six sub-units for men per daily dosage, which are packed separately before being packed into the package, or the package will
5 be provided with means for apportioning of such sub-units.

In another preferred embodiment, the composition of the invention is a liquid nutritrional preparation in a water-containing liquid, in which the solid ingredients are dissolved, suspended, dispersed or emulsified in an amount of 10 to 40 weight %. When the liquid nutritional preparation is intended for
10 drinking, it will usually comprise a flavouring agent as discussed above.

In a further embodiment, the composition of the invention may be in the form of a solid composition such as a nutritional bar, fruit bar, cookie, or a bakery product such as cake, bread or muffin, or a dairy product such as a low-fat spread or margarine.

15 Compositions may form part or all of a prepackaged meal, included chilled and frozen ready-made meals.

Compositions may also be formulated as tablets. Since the quantities of resistant starch and unsaturated fat as well as other ingredients such as binders and flavouring agents result in compositions of at least 7 to 8g, the
20 tablets may be relatively large. Consequently, the tablets will typically be formulated such that they can be chewed prior to swallowing. Alternatively, the compositions may be subdivided into a number of tablets.

Thus compositions of the invention may be provided, for example, in the form of consumer meals, drinks, powders, tablets, health foods, nutritional
25 supplements and animal feeds.

The compositions may form all or part of a calorie controlled diet, for example a calorie-controlled diet having an energy content of from 800 to 1200 kcal per day, or more than 1200 kcal per day, such as more than 2000 kcal per day.

30

Production of foods high in resistant starch and unsaturated fats

Compositions of the invention and foodstuffs high in resistant starch and unsaturated fats are intended as a partial or full replacement for the carbohydrate and fat intake in the normal diet of individuals. One method of achieving the necessary replacement is to provide nutritional supplements
5 together with a reduction in quantities of food or particular food items in the existing diet of an individual. Another method is to provide normal food items in which the carbohydrate and fat content and composition has been modified to provide a foodstuff with increased levels of resistant starch and unsaturated fat (and lower levels of non-resistant starch carbohydrate and saturated fat).

10 Accordingly, the present invention provides a method for producing a composition of the invention which method comprises replacing (i) some or all of the carbohydrate content of a foodstuff or drink with resistant starch and (ii) some or all of the saturated fat content of a foodstuff or drink with unsaturated fat.

15 The present invention also provides a method of preparing a foodstuff which method comprises substituting one or more food components with one or more food components that have a higher resistant starch content and substituting some or all of the saturated fats with unsaturated fats so as to increase the proportion of resistant starch, increase the proportion of
20 unsaturated fats and lower the proportion of saturated fats.

This may be achieved by simple substitution of ingredients during manufacture and/or processing of ingredients, intermediate products or final products to increase the resistant starch and/or unsaturated fat content. A discussion of suitable sources of high resistant starch content ingredients and
25 unsaturated fats is provided above as well as methods for increasing the resistant starch content of starches. Preferably, the resistant starch content is increased to at least 5% by weight of the total carbohydrate content of the foodstuff or composition, more preferably at least 10, 20, 30, 40, 50 or 70% by weight. Preferably the unsaturated fat content is increased to at least 20% by
30 weight of the total fat content of the foodstuff or composition, more preferably at least 30, 40, 50, 60, 70, 80, 90, 95 or 100% by weight.

The above foodstuffs or compositions may be prepared using normal food manufacturing techniques known in the art relevant to any particular foodstuff or composition.

The extent to which the resistant starch and unsaturated fat content can be increased will vary for different food types. By way of example, the amount of resistant starch in currently available white bread is about 1% by weight and the amount of fat (mainly as polyunsaturated fatty acids) is about 2.5% by weight. The resistant starch content of bread may be increased to from 6 to 12% by weight. The amount of fat may be increased to at least 6% in normal white bread (and up to at least 30% in speciality foods).

Methods of modulating carbohydrate/fat metabolism

An object of the present invention is to modify the diet of an individual by increasing their resistant starch intake together with substituting saturated fats with unsaturated effects to achieve the desired metabolic effects. For example, the levels of resistant starch and unsaturated fats, such as polyunsaturated fatty acids, may be increased as compared with the individual's existing dietary intake. In particular, the proportion of resistant starch relevant to total dietary carbohydrate intake and the proportion of unsaturated fats such as polyunsaturated fatty acids relative to total dietary fat intake may be increased.

This manipulation of an individual's diet may be achieved either by a total diet approach or by a single food approach where compositions of the invention rich in resistant starch and unsaturated fats are administered.

Where the total diet approach is used, the increased levels of resistant starch may be provided by one food or food group and the increased levels of unsaturated fats such as polyunsaturated fatty acids may be provided by another food or food group. By way of example, a bakery product, such as bread, which has been specifically formulated to be high in resistant starch may be provided together with a dairy spread formulated to be high in polyunsaturated fatty acids.

The desired metabolic effects include reduced post-prandial plasma glucose concentrations after meal intake, as well as lower plasma insulin levels; a reduction in plasma leptin concentrations together with an increase in satiety; and a decrease in the levels of lipid deposition in white adipose tissue, brown adipose tissue and muscle tissue together with an increase in glycogen synthesis in the liver.

In addition, we have found that transcription of c-fos is modulated significantly in the lateral hypothalamus (LH), ventromedial hypothalamic nucleus (VMH), paraventricular hypothalamic nucleus (PVH), arcuate hypothalamic nucleus (Arc) and dorsomedial hypothalamic nucleus (DMH) (see Figure 6). c-fos transcription is an indicator of neuronal activity (Xin et al., 2000, Brain Research Bulletin, 52: 235-242). Since these regions of the brain are known to play a role in the regulation of energy balance and satiety, the observation that transcriptional activity/neuronal activity in these regions is affected by dietary changes is important. Furthermore, these results are consistent with the changes in satiety and plasma leptin concentrations seen when the resistant starch and fat content of the diet is altered.

Accordingly, the present invention aims to provide methods for regulating carbohydrate and fat metabolism as well as methods for regulating the mechanisms that regulate satiety.

This is typically achieved by administering to the individual a composition of the invention and/or placing an individual on a diet such that the amount of resistant starch in the diet is increased compared with their normal diet.

For example, an individual may be placed on a diet such that in the combined meals, the combined meals contain at least 10 grams of resistant starch or at least 5 grams higher than a comparable meal containing a high quantity of readily digestible starches. It has been found that the consumption of at least 15 grams, preferably at least 20 grams, and more preferably around 30 grams total resistant starch per day with meals provides an improved fat

metabolism of fat, namely increased oxidation of dietary fats and/or mobilisation and utilisation of stored fats, in an individual.

Preferably, the high carbohydrate diet rich in resistant starch provides approximately 50% (it may be higher or lower) of the available calories from carbohydrate, with at least 5 g, preferably 10 g, more preferably at least 20 g, even more preferably at least 25 g, and most preferably at least 30 g resistant starch per day. The consumption of at least 5 g of resistant starch, preferably at least 10 g in a single meal will also have a beneficial effect by increasing fat oxidation.

In addition, the diet may also comprise an increased proportion of unsaturated fats. Preferably, the amount of unsaturated fat in the diet is such that at least 50% of the available calories from fat are provided by the unsaturated fat, more preferably at least 70%.

Respiratory Quotient (RQ) is the molar ratio of carbon dioxide (CO_2) produced to oxygen (O_2) consumed and this ratio varies depending on the energy source being utilised by the body. RQ when oxidising carbohydrate as the sole energy source is theoretically 1.00, RQ when oxidising lipids as the sole energy source is theoretically 0.71. Mixed diets will produce RQs which vary between these two theoretical values.

The results shown herein demonstrate that the RQ is lowered in individuals consuming a diet high in resistant starch (see Figure 13). This indicates that the resistant starch is causing a shift in fuel mobilisation that favours fat oxidation over carbohydrate oxidation.

Thus the present invention provides a method for regulating carbohydrate and fat metabolism in an individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 20% of the individual's saturated fat intake with unsaturated fat.

Preferably at least 7, 10, 20, 30, 40, 50 or 60% of the individual's daily carbohydrate intake is replaced with resistant starch.

Preferably at least 5, 7, 10, 20, 30, 40, 50, 60 or 70% of the individual's daily saturated fat intake is replaced with unsaturated fat.

The present invention also provides method for regulating carbohydrate and fat metabolism in an individual which method comprises providing at least 5 5% of the individual's daily carbohydrate intake as resistant starch and at least 60% of the individual's fat intake as unsaturated fat.

Typically, the amount of resistant starch provided as a proportion of daily carbohydrate intake is in the range from 5 to 90%, preferably from 10 to 60%. Expressed as a percentage of the total diet, it is preferred that the amount 10 of resistant starch is at least 5%, typically from 5 to 45%, preferably from 5 to 30% of the total diet based on calorie content.

Typically, the amount of unsaturated fat provided as a proportion of daily fat intake is in the range from 60 to 95%, preferably at least 60, 70, 80 or 90%. Expressed as a percentage of the total diet, it is preferred that the amount 15 of unsaturated fat is at least 15%, typically from 15 to 30%, such as at least 20 or 30% of the total diet based on calorie content.

The compositions and methods of the invention may be used to achieve one or more of the following:

An enhancement of fat utilisation in an individual, for example a 20 reduction in fat accumulation (in white adipose tissue, brown adipose tissue and/or muscle tissue), and/or an increase in fat oxidation (which may be evidenced by a reduction in RQ).

A reduction of plasma leptin concentrations;

An increase in satiety in an individual for a given caloric intake;

25 Treatment of obesity;

A lowering of the incidence or risk of obesity in an individual;

A reduction in the incidence or risk of non-insulin dependent diabetes mellitus in an individual.

A reduction in the post-prandial plasma glucose and/or insulin levels in 30 an individual following food consumption by the individual;

Regulation of an individual's body mass (for example to increase or decrease the individual's body mass index or to maintain a desired body mass index);

Body shaping; and

- 5 An improvement in energy utilisation during exercise such as sports activities e.g. to improve sports performance.

Individuals predisposed to obesity or non-insulin dependent diabetes mellitus can be placed on the diet as a means of preventing or delaying the onset of the disease state. Also individuals already suffering from these
10 conditions can effect these changes to the diet as part of the treatment regime.

The present invention is applicable for animals and humans by manipulating the diet through feed, food, supplements and pharmaceuticals. In the case of humans, the present invention is typically applicable to all age ranges, such as prepubescents, young adults (18 to 24 years of age), middle
15 aged adults (from about 35 to 50) and older adults (over 50 years of age). The precise nature of the diet will vary according to the symptoms, risk factors, objective of treatment and age of the individual concerned and can be readily determined by a dietitian, physician or other suitably qualified person.

Throughout this specification, unless the context requires otherwise,
20 the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

In order that the present invention may be more clearly understood,
25 preferred forms will be described with reference to the following examples and drawings, which are illustrative only and non-limiting.

Description of the Figures

- 30 Figure 1. Post-prandial plasma glucose concentrations in response to a) cooked or b) uncooked starches of different amylose concentration. Values for each diet group (n=7) are expressed as means $\pm$ s.e.

Figure 2. Post-prandial plasma insulin concentrations in response to a) cooked or b) uncooked starches of different amylose concentration. Values for each diet group (n=7) are expressed as means $\pm$ s.e.

5

Figure 3. Incremental area under the curve (AUC) for a) glucose and b) insulin in response to meals of different amylose concentration. (*) represents a significant difference (p=0.05) from the 0% amylose group in the same category (ie cooked or uncooked). (#) represents a significant difference (p=0.05) from the uncooked starch of the same amylose concentration. Values for each diet group (n=7) are expressed as means $\pm$ s.e.

10

Figure 4. a) Plasma glucose (mmol/L) concentrations of the four dietary groups in response to a 2-hour intravenous glucose challenge (10%). Values for each diet group (n=12) are expressed as means $\pm$ s.e. The saturated fat/amylopectin diet is significantly different from the n-3/amylopectin diet (p=0.05), while the n-3/amylose diet is significantly different from the n-3/amylopectin diet (p=0.001). b) Plasma insulin (ng/ml) concentrations of the four dietary groups in response to a 2-hour intravenous glucose challenge (10%). Values for each diet group (n=12) are expressed as means $\pm$ s.e. The saturated fat/amylose diet is significantly different from the n-3/amylose diet (p=0.001), while the n-3/amylopectin diet is significantly different from the n-3/amylose diet (p=0.05).

20

Figure 5. Fasting plasma leptin concentrations (ng/ml) in the four dietary groups following a 16-week dietary protocol. Values for each diet group (n=12) are expressed as means $\pm$ s.e. There were significant differences between the starch groups (p=0.05), but not between fat groups.

25

Figure 6. Fasting c-fos activation of different hypothalamic regions of the brain in the four dietary groups following a 16-week dietary protocol. Values

30

for each diet group ($n=5$, $n=1$ for *saturated fat/amylose* group) are expressed as means $\pm$ s.e. C-fos values of the various regions of the brain were statistically significant at ($p=0.001$) for DMH, ($p=0.01$) for ARC, ($p=0.005$) for LHA, ($p=0.001$) for PVN, and ($p=0.05$) for VMH. [Key: lateral hypothalamus (LH),
 5 ventromedial hypothalamic nucleus (VMH), paraventricular hypothalamic nucleus (PVH), arcuate hypothalamic nucleus (Arc) and dorsomedial hypothalamic nucleus (DMH)].

Figure 7. Rate of lipogenesis (microgram atom H/min/g) at 1 hour and 2 hours
 10 in brown adipose tissue (BAT) in response to starches of different amylose concentration. Values for each diet group ($n=8$) are expressed as means $\pm$ s.e. Amylose and amylopectin fed rats were significantly different at the 2-hour time point ($p=0.01$).

15 Figure 8. Rate of lipogenesis (microgram atom H/min/g) at 1 hour and 2 hours in gastrocnemius muscle tissue in response to starches of different amylose concentration. Values for each diet group ($n=8$) are expressed as means $\pm$ s.e.

Figure 9. Rate of lipogenesis (microgram atom H/min/g) at 1 hour and 2 hours
 20 in white adipose tissue (WAT) in response to starches of different amylose concentration. Values for each diet group ($n=8$) are expressed as means $\pm$ s.e. Amylose and amylopectin fed rats were significantly different at the 1-hour time point ($p=0.01$).

25 Figure 10. Rate of lipogenesis (microgram atom H/min/g) at 1 hour and 2 hours in liver tissue in response to starches of different amylose concentration. Values for each diet group ($n=8$) are expressed as means $\pm$ s.e.

Figure 11. Rate of lipogenesis (microgram atom H/min/g) at 1 hour and 2 hours
 30 in liver tissue in response to starches of different amylose concentration. Values for each diet group ($n=8$) are expressed as means $\pm$ s.e.

Figure 12. Rate of glycogenesis (microgram atom H/min/g) at 1 hour and 2 hours in gastrocnemius muscle tissue in response to starches of different amylose concentration. Values for each diet group (n=8) are expressed as means $\pm$ s.e.

Figure 13. Change in RQ in response to resistance starch in the diet. Two weeks after commencing a DS or RS diet (day 14), subjects returned for a follow-up fasting blood sample and a 3 hour meal test. The test meal consisted of 60 g breakfast cereal, 250 mL Lite White milk, 1 slice of bread (toasted), 1 muffin (toasted), 10g of Canola margarine and 20 g of jam. Results are expressed as mean $\pm$ SEM (n = 12 for DS solid circles, n = 11 for RS, open circles). *p < 0.03 for difference from the RS group at the same time point.

EXAMPLES

Example 1 - Acute Study

Rats were provided with standard rat chow for one week before surgical implantation of canulae. Canulations were then performed one week prior to conducting the acute meal tests. One week post canulation, rats were fasted overnight. The following morning, the rats were presented with one gram carbohydrate /kg body weight and post-prandial blood samples were taken over a 2 hour period. Two hours after eating, the rats were sacrificed and their tissues were harvested for later analysis.

Table 1. Diet composition of acute meals.

Diet Composition of Acute Meal Test Diet	
Ingredients	grams/kg (diet)
Starch	514
Sucrose	85
Methionine	2

Bran	50
Gelatine	19
Sunflower oil (ml/kg)	25
Canola oil (ml/kg)	25
Casein	200
Vitamins	13
Minerals	67
TOTAL	1000

The results are shown as Figures 1 to 3.

5 **Example 2 - Chronic Study**

Offspring of lab bred rats were injected at 2 days of age with Streptozotocin, to induce a non-insulin diabetic condition, or with standard buffer solution. At 8 weeks of age, the rats were fasted overnight and given a glucose tolerance test to determine their diabetic state. Rats were divided into
10 diabetic or non-diabetic groups and fed test diets for 8 weeks. Metabolic rates were obtained on each rat at week 7 of the feeding period. Upon completion of feeding, glucose tolerance tests were repeated and blood samples obtained. Rats were then sacrificed and brains and muscle tissues were harvested for later analysis.

15

The results are shown in Figures 4 to 6 and Table 2.

Table 2. Body weights, basal plasma glucose and insulin, and kcal of diet consumed during meal tests.

20

Diet Group	Weight (g)	Basal Glucose (mM)	Basal Insulin (ng/ml)	kcal Consumed/kg Body Weight
<u>Uncooked Starch</u>				
0%	272.5 ± 11.0	8.70 ± 0.22	0.50 ± 0.07	3.79 ± 0.48
27%	271.1 ± 8.0	8.32 ± 0.64	0.51 ± 0.07	3.97 ± 0.53
60%	268.1 ± 4.3	8.48 ± 0.30	0.47 ± 0.08	4.26 ± 0.20
85%	268.8 ± 8.4	8.18 ± 0.43	0.44 ± 0.05	4.18 ± 0.32

<u>Cooked Starch</u>				
0%	305.0 ± 14.0	7.41 ± 0.49	0.42 ± 0.09	4.81 ± 0.52
27%	320.8 ± 12.4	6.75 ± 0.29	0.50 ± 0.14	4.39 ± 0.71
60%	306.4 ± 16.3	7.30 ± 0.22	0.53 ± 0.12	4.99 ± 0.44
85%	319.8 ± 16.9	7.38 ± 0.32	0.68 ± 0.11	5.23 ± 0.70

Example 3 - Absorption Study

Rats were provided with standard rat chow for one week before surgical implantation of canulae. Canulations were then performed one week prior to conducting the acute meal tests. One week post canulation, rats were fasted overnight. The following morning, animals were presented with one gram carbohydrate per kg body weight. After eating, rats were injected with radioactive marker and post-prandial blood samples were taken over a 2 hour period.

Rats were sacrificed at either 1 hour or 2 hours after feeding and their tissues were harvested for later analysis.

Table 3. Diet Composition, Total Energy, and Percent Energy of the long-term diets.

Ingredients	grams/kg (diet)	energy (kcal)	% energy
Sucrose	150	600	12.6
Protein	140	560	11.8
Starch	450	1800	37.8
fat	200	1800	37.8
fibre	50		
Vit&min	10		
TOTAL	1000	4760	100

The results are shown as Figures 7 to 12.

Discussion of results obtained in Examples 1 to 3

c-fos activity

The effect of diet on neuronal (c-fos) activity is quite interesting, when
5 looking at its impact on total energy balance. The lateral hypothalamus (LHA)
is thought to be the feeding center within the parasympathetic system, which is
associated with positive energy balance. The ventromedial hypothalamus
(VMH), however, is considered the satiety centre of the sympathetic nervous
system and represents negative energy balance. Figure 8 illustrates that diets
10 high in unsaturated fats and resistant starch have decreased activation of the
hunger centre (LHA) and increased levels of activation of the satiety center,
whereas diets high in saturated fat and low in resistant starch have the opposite
effect. When taken together (LHA/VMH), these values determine total energy
balance.

15

Absorption

Preliminary results from RQ data suggest a shift in substrate utilisation,
from glycogen to fat oxidation, when increasing the proportion or percentage of
resistant starch. However, it is unclear if, when and where these changes
20 actually occurred. Figures 7 through 12 illustrate the effect of resistant starch
on the glycogen synthesis/utilisation and lipid synthesis/oxidation of various
tissues, following ingestion of starches of different concentration. Figures 7
and 9 show significant differences in the rate of lipogenesis within brown
adipose and white adipose tissues and a trend toward increased glycogenesis
25 within liver tissue. This confirms that consumption of resistant starch,
especially long-term, may in fact shift substrate utilisation from glycogen to fat
oxidation.

Leptin levels

30 leptin is a protein synthesized in adipose tissue and is thought to inhibit
food intake and increase satiety. Leptin receptor is found in the hypothalamus
of the brain and may be a key link between the neuronal (c-fos) and hormonal

systems and their effect on caloric homeostasis. Although other studies have shown differences in leptin levels between groups fed saturated fat and unsaturated fat, Figure 5 shows significant differences only between groups with different starch concentrations, although there was a trend toward higher
5 leptin levels in the unsaturated fat group. Differences between the starch groups can be explained by the large difference in body and fat weights of the animals, as there was substantial weight loss with chronic resistant starch consumption. This weight loss could be attributed, in part, to the substrate utilisation shift we noted in the absorption study. Also, with the fat loss will be
10 a decrease in leptin production.

Example 4 – Effect of Resistant Starch Diet on RQ values in Humans

METHODS

15 Twenty-four healthy males (19 - 34 years of age) participated in the present study. Approval for this work was granted by the University of Wollongong Human Ethics Committee and full written consent was obtained from all subjects prior to commencement of the trial.

Subjects were randomly divided into two groups. The first group
20 received a traditional starch (TS) diet, low in resistant starch, whereas the second group received a Hi-maize™ (HM) diet, high in resistant starch. The TS diet consisted of standard commercially available products whereas the HM diet consisted of commercially available product containing [Hi-maize™ (Table 1). For the TS group, mean and SEM values for age, height and weight were
25 22.3 ± 0.6 years, 180 ± 3.1 cm. and 73.5 ± 3.7 kg, respectively. For the HM group, mean and SEM values for age, height and weight were 23.5 ± 0.8 years, 185 ± 1.8 cm, and 74.1 ± 2.4 kg, respectively.

All subjects were requested to eat at least 60 g breakfast cereal, 4 slices of white bread, and 2 muffins per day plus 3 pasta meals (125 g servings) per
30 week for 14 days. An excess of these foods was provided such that subjects could exceed the intake guidelines if necessary as all participants were exercising regularly (4-8 times per week). All subjects were advised not to eat

foods containing a significant amount of resistant starch (eg. legumes, green bananas and bismati rice) during the study in effort to control the 'background' intake of resistant starch (ie. resistant starch from sources other than those provided as part of the study). All foods supplied to subject were donated by
 5 Buttercup Bakeries, Uncle Toby's Company Ltd, and New Zealand Starch Products on behalf of Starch Australasia Ltd.

Before commencing the allotted diet (day 0), a fasting venous blood sample (antecubital) was taken from each subject followed by a diet history interview and thorough explanation of the dietary guidelines for the study.
 10 Two weeks after commencing the diet (day 14), subjects returned for a follow-up fasting blood sample and a 3 hour meal test. The test meal was either TS or HM, based upon the subject's diet over the two week study period, and consisted of 60g breakfast cereal, 250 ml Lite White milk, 1 slice of bread (toasted), 1 muffin (toasted), 10 g of Canola margarine and 20 g of jam.

15 Venous blood samples (antecubital) were taken 30, 60, 120 and 180 min post-ingestion of the test meal. Respiratory quotient (RQ) measurements were taken at 0, 60, 120 and 180 min after ingestion of the test meal using a Datas Deltatrac II (Helsinki, Finland). In addition, all blood samples were analysed for serum glucose, serum insulin, plasma cholesterol, plasma total lipid and
 20 plasma free fatty acid concentration.

Table 4. Resistant starch (RS) content of foods consumed (% w/w)

Traditional starch group (TS)			Hi-maize™ group (HM)		
	Product	RS content	Product	RS content	
Cereal	Uncle Toby's MaxNRG	0.7	Uncle Toby's Grinners	3.4	
Bread	Buttercup Super Sandwich Maker	0.8	Buttercup Wonder White	2.9	
Muffins	Buttercup English Muffins	0.8	Wonder White Muffins	1.6	

Pasta	Vetta pasta Spirals	<0.1	Hansell Pasta Spiral	1.5
	TOTAL per meal	2.4		9.4

Table 5. Actual nutrient intake during the dietary intervention as assessed from diet history records and subject's daily food check list. Values indicated as a percentage represent the percentage of total calorie intake.

5

	Traditional starch group	Hi-maize™ group
Energy intake (kJ/d)	13871 ± 3500	13258 ± 3100
Carbohydrate (%)	53 ± 1.0	57 ± 1.4
Resistant starch (g/d)	2.4	9.4
Protein (%)	17 ± 0.3	18 ± 0.2
Total Fat (%)	27 ± 0.3	24 ± 0.2
Saturated fat (%)	12 ± 0.1	11 ± 0.1
Mono-unsaturated fat (%)	10 ± 0.1	8 ± 0.1
Poly-unsaturated fat (%)	5 ± 0.1	5 ± 0.04

RESULTS

Of the 24 subjects recruited, one subject from the HM group was found to be insulin resistant according to World Health Organisation (WHO) criteria and was eliminated from the study. Total energy intake and macronutrient composition of the diet did not significantly differ between the TS and HM groups (Table 5).

There was no difference in fasting RQ values between the TS and HM groups (data not shown). RQ values ranged between 0.83 and 0.91 and were plotted as ΔRQ which represents the difference between the RQ at each time point and that at 0 min (Figure 13). The ΔRQ at 80 and 120 min after meal ingestion showed no difference between the TS and HM groups. After 180 min. however, the ΔRQ for the HM group was approximately 50% of that for the TS group.

Discussion

Two groups of healthy males (age 18-34 years) consumed a high carbohydrate diet containing either traditional starch (TS) products low in resistant starch or Hi-maize™ (HM) products high in resistant starch content for two weeks. RQ measurement and blood samples were taken post-meal ingestion to be analysed for glucose, insulin, free fatty acid (FFA), cholesterol and total lipid concentration. At 3 hours the ΔRQ for the HM group (0.04 ± 0.01) was approximately 50% of that for the TS group (0.09 ± 0.02 ; $p < 0.01$). This data provides evidence that a diet high in resistant starch causes an acute shift in fuel utilisation that favours fat oxidation over carbohydrate oxidation with the consumption of elevated levels of dietary resistant starch.

In absolute terms, carbohydrate was the primary source of energy at 1, 2 and 3 hours post-meal ingestion as RQ values ranged from 0.90 to 0.92. The decrease in RQ which was observed in the HM group relative to the TS group 3 hours after eating represents an increase in fat oxidation. Although the magnitude of this decrease in RQ (0.05 units) seems small, it accounts for a large difference in fat oxidation. For example, if subjects in the TS group were oxidising 50% fat and 50% carbohydrate, the observed decrease in RQ would mean that subjects in the HM group were oxidising 87% fat and 33% carbohydrate. This substantial difference in fuel utilisation is of particular interest, especially since the difference in the total resistant starch content between the HM and TS diets was relatively low. The meal used for the acute assessment contained approximately four times as much resistant starch as the TS diet (28.2% versus 7.2% (w/w), respectively). A larger increase in the amount of resistant starch may result in an even larger effect on fuel utilisation.

Resistant starch consumption caused an acute increase in fat oxidation. In addition, consumption of a high carbohydrate diet, irrespective of resistant content, lowered fasting plasma FFA concentrations. Taken together, these results indicate that a high carbohydrate diet, rich in resistant starch may be beneficial for those who suffer metabolic diseases in which plasma FFA

oversupply is symptomatic such as obesity and non-insulin dependent diabetes mellitus.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the
5 specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

All publications mentioned in the above specification are herein incorporated by reference. Any discussion of documents, acts, materials,
10 devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia or any other country
15 or territory before the priority date of each claim of this application.

CLAIMS

1. A method for regulating carbohydrate and fat metabolism in an individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
2. A method according to claim 1 wherein at least 80% of the individual's fat intake is as unsaturated fat.
3. A method for enhancing fat metabolism in an individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
4. A method according to claim 2 wherein the enhancement of fat metabolism includes a reduction in fat accumulation and/or an increase in fat oxidation.
5. A method for reducing plasma leptin concentrations and increasing satiety in an individual, which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
6. A method of treating an individual suffering from obesity, which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
7. A method of lowering the incidence of obesity in an individual, which method comprises replacing at least 5% of the individual's daily carbohydrate

intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.

8. A method of lowering the incidence of non-insulin dependent diabetes mellitus in an individual, which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
9. A method of reducing the post-prandial plasma glucose and/or insulin levels in an individual following food consumption by the individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
10. A method of controlling an individual's body mass which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
11. A method of preparing a foodstuff for use in a method according to any one of claims 1 to 10 which method comprises substituting constituents with a low resistant starch content with constituents with a high resistant starch content and substituting some or all of the saturated fats with unsaturated fats.
12. A method according to claim 11 wherein at least 5% of the carbohydrate content is replaced with resistant starch content and at least 10% of the saturated fat content is replaced with unsaturated fat.
13. A composition comprising at least 2g of resistant starch and at least 2.g of unsaturated fat wherein the resistant starch is present in a proportion of at least 5% by weight of the total starch content.

14. A composition according to claim 13 wherein the resistant starch is present in a proportion of at least 5% by weight of the total carbohydrate content.
- 5 15. A composition according to claim 14 or claim 15 wherein some or all of the resistant starch is, or is derived from, a high amylose maize starch having an amylose content of 50% or more by weight.
- 10 16. A composition according to any one of claims 13 to 15 wherein the unsaturated fat is present in a proportion of at least 25% by weight of the total fat content.
- 15 17. A composition according to claim 16 wherein the unsaturated fat is present in a proportion of at least 50% by weight of the total fat content.
18. A composition according to claim 17 from which saturated fats are substantially absent.
- 20 19. A composition according to any one of claims 13 to 18 wherein the unsaturated fat is selected from one or more of a mono-unsaturated fat, a poly-unsaturated fat, an omega-3 fat, and an omega 6 fat.
- 25 20. A composition according to any one of claims 13 to 19 which further comprises at least one further ingredient selected from the group consisting of a flavouring agent, a vitamin source, a mineral source, an electrolyte, and a trace element.
- 30 21. A composition according to any one of claims 13 to 20 in the form of a low calorie diet having an energy content of from 800 to 1200 kcal per day.

22. A composition according to any one of claims 13 to 20 in the form of a diet having an energy content of more than 1200 kcal per day.

23. A composition according to any one of claims 13 to 20 in the form of a diet having an energy content of more than 2000 kcal per day.

24. A composition according to any one of claims 13 to 23 in the form of a powdery mixture, said powdery mixture being soluble, suspendable, dispersible or emulsifiable in a water-containing liquid.

10

25. A composition according to any one of claims 13 to 23 in the form of granules.

26. A method for regulating carbohydrate and fat metabolism in an individual which method comprises administering to the individual a composition according to any one of claims 13 to 25.

27. A method of enhancing fat utilisation in an individual, which method comprises administering to the individual a composition according to any one of claims 13 to 25.

28. A method for reducing plasma leptin concentrations and increasing satiety in an individual, which method comprises administering to the individual a composition according to any one of claims 13 to 25.

25

29. A method of treating an individual suffering from obesity, which method comprises administering to the individual a composition according to any one of claims 13 to 25.

30. A method of lowering the risk of obesity in an individual, which method comprises administering to the individual a composition according to any one of claims 13 to 25.

5 31. A method of lowering the risk of non-insulin dependent diabetes mellitus in an individual, which method comprises administering to the individual a composition according to any one of claims 13 to 25.

10 32. A method of reducing the post-prandial plasma glucose and/or insulin levels in an individual following food consumption by the individual which method comprises administering to the individual a composition according to any one of claims 13 to 25.

15 33. A method of of controlling an individual's body mass which method comprises administering to the individual a composition according to any one of claims 13 to 25.

34. A composition according to any one of claims 13 to 25 for use in a method according to any one of claim 26 to 33.

20

35. Use of a composition according to any one of claims 13 to 25 in the manufacture of a medicament for use in a method according to any one of claim 26 to 33.

25 36. A foodstuff comprising a composition according to any one of claims 13 to 22.

37. A prepackaged meal comprising at least one meal component which comprises a composition according to any one of claims 13 to 25.

30

38. A method for producing a composition according to any one of claims 13 to 25 which method comprises replacing (i) some or all of the carbohydrate content of the composition with resistant starch and (ii) some or all of the saturated fat content of the composition with unsaturated fat.

Figure 1





Figure 2




Figure 3




Figure 4




Figure 5






Figure 6



yy

Figure 7



VJ

Figure 8






Figure 9




47

Figure 10




vs

Figure 11




XY

Figure 12



50

Figure 13



51

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU01/00392

A. CLASSIFICATION OF SUBJECT MATTER												
Int. Cl. ³ : A23L 1/308, 1/30												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols)												
SEE "ELECTRONIC DATA BASE" BOX BELOW												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base searched during the international search (name of data base and, where practicable, search terms used)												
WPIDS: resistant starch, unsaturated fat, A23L 001/30?												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X	ASP. N.G., <i>Advances in Experimental Medicine and Biology</i> , 1997, Vol. 427, pages 201-310	1-38										
X	KRIS-ETHERTON, P.M., <i>Journal of Cardiovascular Risk</i> , 2000, Vol. 7, No. 5, pages 333-337	1-38										
X	EP 0 506 166 A (UNILEVER N.V., et al.) 30 September 1992 whole specification	1-38										
☒ Further documents are listed in the continuation of Box C ☒ See patent family annex												
* Special categories of cited documents: <table border="0"><tr><td>"A" document defining the general state of the art which is not considered to be of particular relevance</td><td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to undermine the principle or theory underlying the invention</td></tr><tr><td>"E" earlier application or patent but published on or after the international filing date</td><td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>"L" documents which may throw doubts on priority date(s) or which is used to establish the publication date of another citation or other special reason (as specified)</td><td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>"O" document referring to an oral disclosure, use, exhibition or other means</td><td>"A" document member of the same patent family</td></tr><tr><td>"P" document published prior to the international filing date but later than the priority date claimed</td><td></td></tr></table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to undermine the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" documents which may throw doubts on priority date(s) or which is used to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"A" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to undermine the principle or theory underlying the invention											
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" documents which may throw doubts on priority date(s) or which is used to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"A" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 18 June 2001		Date of mailing of the international search report 5 July 2001										
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6283 3929		Authorized officer JAMIE TURNER Telephone No : (02) 6283 2071										

INTERNATIONAL SEARCH REPORT		International application No. PCT/AU01/00392
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 550 060 A (KANEAGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA) 7 July 1993 whole specification	1-38
X	EP 0 747 397 A (NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION) 11 December 1996 whole specification	1-38
X	EP 0 846 704 A (CERESTAR HOLDING B.V.) 10 June 1998 whole specification	1-38
X	WO 97/35889 A (OPTA FOOD INGREDIENTS, INC.) 2 October 1997 whole specification	1-38

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU01/00392

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
EP	506166	CA	2063784	JP	5236908		
EP	550060	JP	6065082	US	5268367		
EP	747397	AU	52271/96	CA	2178128	JP	9012601
		US	5593503	US	5902410		
EP	846704	AU	46846/97	CA	2223149	JP	10191931
		US	6043229				
WO	9735889	AU	24246/97	CA	2249313	EP	889908
		US	5849090				
END OF ANNEX							



54

Industria y Comercio
SUPERINTENDENCIA

SUPERINDUSTRIA Y COMERCIO
Radicación : 02090222 00000000 Folios: 54
Fecha (MM): 2002-10-07 16:36:27
Trámite : 011 PCT-PATENT 379 FASE NNCI 411 PRESENTAR
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

NIT : 000176009-2

RECIBO OFICIAL DE CAJA : 02 - 69,106
FECHA : SEPTIEMBRE 30 DE 2002


***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	Vr. PAGO
CAVELIER ABOGADOS	CONSIGNACION	BANCO POPULAR	050-00110-6	7030336	30/09/2002	23,260,000.00

***** CONCEPTO *****

CANT. CONTABILITICO	CONCEPTO	TOTAL CONCEPTO
1 50005-01-01 SOLICITUDES	1 TRAMITES DE SOL. DE PATENTE DE IN	378,000.00
	TOTAL :	\$ 378,000.00

CON: TRESCIENTOS SETENTA Y OCHO MIL PESOS

RESPONSABLE : 

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

Colo 13487-841-001-5

Carrera 13 No. 27-00 Pisos 5, 7 y 10
Conmutador 382 0840
Fax 350 5220
E-mail: info@sic.gov.co
www.sic.gov.co
Bogotá, D.C., Colombia

114
55

REQUISITOS NECESARIOS PARA PRESENTACION Y AGILIZACION DEL TRAMITE

	USUARIO	RADICADOR
PATENTE DE INVENCION ✓	()	() ✓
- Indicación de que se solicita la concesión de una patente.	()	() ✓
- Datos de identificación del solicitante o de la persona que se presenta la solicitud.	()	() ✓
- Descripción de la invención.	()	() ✓
- Dibujos de ser estos pertinentes.	()	() ✓
- Comprobante de Pago de las tasas establecidas.	()	() ✓
COMPLETA () ✓	INCOMPLETA ()	()
DISEÑO INDUSTRIAL ()		
- Indicación de que se solicita el registro de Diseño Industrial	()	()
- Datos de identificación del solicitante o de la persona que presenta la solicitud.	()	()
- Representación gráfica y fotográfica del Diseño Industrial o muestra del Material que incorpora el diseño.	()	()
- Comprobante de pago de las tasas establecidas	()	()
COMPLETA ()	INCOMPLETA ()	()
ESQUEMA DE TRAZADO ()		
- Indicación de que solicita el registro de un Esquema de trazado.	()	()
- Datos de identificación del solicitante o de la persona que presenta La solicitud.	()	()
- Representación gráfica del esquema de trazado	()	()
- Comprobante de pago de las tasas establecidas.	()	()
COMPLETA ()	INCOMPLETA ()	()

Firma Responsable:

[Firma]

Fecha:

Carrera 13 No. 27-00 Pisos 5 y 10
Conmutador: 334 12 21
Fax: 281 31 25
Santa Fe de Bogotá, D.C., Colombia



2020
Bogotá, D.C.,

Doctor:
Emilio Ferrero
Apoderado
Penford Australia Limited

Oficio N° 07219

ASUNTO:	Radicación N°	02-90222
	Solicitud internacional	PCT/AU01/00392
	Fecha inicio fase nacional	06/11/2002
	Trámite	011
	Evento	379
	Actuación	430
	Folios	001

Como resultado del examen de forma, realizado con fundamento en el artículo 38 de la Decisión 486 de la Comisión de la Comunidad Andina, artículo 27 del Tratado de Cooperación en Materia de Patentes (PCT), regla 51 bis del Reglamento y Circular Única de la Superintendencia de Industria y Comercio, se le comunica que:

- ☐ La solicitud no contiene la copia del documento en que consta la cesión del derecho a la patente del inventor al solicitante o a su causante. (Art. 26-k) Decisión 486).
- ☐ La solicitud no contiene el poder debidamente otorgado, con el lleno de los requisitos exigidos por los artículos 63 y subsiguientes del Código de Procedimiento Civil. Adicionalmente, deberá presentar el documento que acredita la existencia y representación legal de la sociedad solicitante, cuando ésta fuere persona jurídica.

En cumplimiento de lo dispuesto por el artículo 39 de la Decisión 486, se le requiere para que dentro del término de dos meses siguientes a la fecha de notificación del presente oficio, complete los requisitos anteriormente enunciados. En caso de no dar cumplimiento al presente requerimiento, la solicitud se considerará abandonada y perderá su prelación.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única N° 10 de 2001.


ALIX CARMENZA GESPEDES DE VERGEL
Jefe de la División de Nuevas Creaciones.

05 SET. 2003

El anterior requerimiento fue notificado por fijación en lista de fecha, _____.